Cylex Closes Third Round Of Private Financing With Investment From Siemens Venture Capital GmbH
Cylex Incorporated, a life sciences company and leader in immune system testing, today announced that it has now completed a final close on its third round of private financing, with an investment from Siemens Venture Capital, GmbH and other private investors. Cylex raised a total of $20.5 million in this round of financing. The private offering was co-led by Channel Medical Partners and Canaan Partners. Asante Partners acted as advisers to Cylex in the financing.
“It is particularly noteworthy that we now have the top two diagnostic companies in the world among our investor group at Cylex, with Siemens joining Roche with their investment support. The confidence of our strategic investors continues to confirm the potential for our flagship product, ImmuKnow™, as well as the potential of the immune monitoring market,” said Judith A. Britz, Ph.D., Chairman and CEO of Cylex. “We certainly welcome Siemens’ commitment and support.”
Tony Bihl, President of Siemens Medical Solutions Diagnostics, said, “Cylex has a unique and elegant technology for quantification of immune function, which is complementary to our own efforts related to immunosuppressant drugs.”
Anupendra Sharma, Investment Partner at Siemens Venture Capital, added, “Judy Britz has led the Cylex team in successfully validating the test scientifically, while driving adoption among clinicians. With today’s successful penetration of the transplant market, the company is just scratching the surface of ImmuKnow’s potential, and we look forward to helping them commercialize it for other applications.”
Cylex is a life science company and a leader in the development and manufacture of unique products that use the immune system for predicting and managing human health. It is the first and only company to offer a patent- protected, FDA-cleared cellular assay of immune system function, ImmuKnow™, which measures the vitality of a patient’s immune system from a single drop of blood. The company’s products enable physicians to better manage and personalize the treatment of life-threatening diseases, such as HIV, HCV, cancer, diabetes, autoimmune and other disorders, as well as serious conditions associated with organ transplantation.
ImmuKnow™ is currently being incorporated into patient protocols at leading U.S. hospitals and clinics. It is the only standardized cellular assay, easily performed in the lab, with quick and accurate results. By optimizing therapy, ImmuKnow™, helps the physician lower the cost of treatment and improve treatment outcome, reduce the side effects of drugs, and enhance the patient’s prospects for long-term quality of life
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.